Loading...
Loading...
OMGA| Name | Value |
|---|---|
| Revenues | 0.8M |
| Cost of Revenue | 1.9M |
| Gross Profit | -1.0M |
| Operating Expense | 24.3M |
| Operating I/L | -22.9M |
| Other Income/Expense | 0.7M |
| Interest Income | 0.7M |
| Pretax | -22.2M |
| Income Tax Expense | -1.9M |
| Net Income/Loss | -22.2M |
Omega Therapeutics, Inc. is a biopharmaceutical company focused on developing OMEGA Epigenomic Programming platform to manipulate gene expression and cell function. The company's OEC candidates aim to regulate gene expression for potential treatments in chronic liver diseases, diabetes, corneal regeneration, idiopathic pulmonary fibrosis, hair growth inhibition, and lung cancer. Additionally, they are developing OTX-2002 to target c-Myc, an oncogene. Omega Therapeutics generates revenue through the development and potential commercialization of these innovative epigenetic therapies, aiming to address unmet medical needs and improve patient outcomes.
